Mark Gordon is the founder and CEO of Diviner, a disruptive startup applying prediction science and biopharma experts to forecast clinical trial outcomes and their impact on biotech stocks. Mark has spent 20 years helping biotech and pharma companies adopt software, data and analytics to improve R&D pipelines and get drugs to market. During the last decade he has held leadership positions in product strategy, product management, innovation, and M&A in large business intelligence units at Informa and Thomson Reuters.

© 2024 BioFutureTM. All Rights Reserved

Produced by